Stephen Mallett

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Michael E. Wechsler, Praveen Akuthota, David Jayne et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

Florence Roufosse, Jean‐Emmanuel Kahn, Gerald J. Gleich et al. · Journal of Allergy and Clinical Immunology · 2012 · 177 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

Jonathan Steinfeld, Eric Bradford, Judith C. Brown et al. · Journal of Allergy and Clinical Immunology · 2018 · 150 citations · Full text

Life Sciences, Clinical Sciences, Pharmacotherapy +16

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

Peter C. Taylor, Emilia Quattrocchi, Stephen Mallett et al. · Annals of the Rheumatic Diseases · 2011 · 124 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Emilia Quattrocchi, Mikkel Østergaard, Peter C. Taylor et al. · PLoS ONE · 2016 · 26 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17